Global Ocular Drug Delivery System Market

Sample 👉 www.marketsintrend.com/sample-repor...

The global ocular drug delivery system market—~USD 16–21 billion today—is growing at 6–9% CAGR, led by implants, sustained‑release, and injectables.

#OcularDrugDelivery #Ophthalmology #MedTech #Biopharma

Arrivent Biopharma Hits $27.25 52-Week High Arrivent Biopharma reached a 52-week high of $27.25 on Apr 9, 2026 (Investing.com), prompting focused institutional due diligence on liquidity, catalysts and cash runway.

Arrivent Biopharma Hits $27.25 52-Week High: Arrivent Biopharma reached a 52-week high of $27.25 on Apr 9, 2026 (Investing.com), prompting focused institutional due diligence on liquidity, catalysts and cash runway. 👈 Read full analysis #Biopharma #Investing #StockMarket #Biotech #Investment

Close-up of a person’s hands holding a pen and flipping through pages, likely reviewing or signing medical or clinical trial documents.

Welcome to Wednesday Words, where I will define one word used in biotechnology or biopharma each Wednesday morning!

If you want to learn more, check out: sbee.link/um3pbdfwyq
#wednesdaywords #biotechnology #biopharma #ClinicalTrials #AdverseEvent #AE #science

New Insights from Courier Health's 2026 Patient-Centricity Report in Biopharma Courier Health has published its 2026 report on patient-centricity in biopharma, highlighting significant gaps in data infrastructure and AI adoption.

New Insights from Courier Health's 2026 Patient-Centricity Report in Biopharma #United_States #New_York_City #Biopharma #Courier_Health #Patient-Centricity

Jeito closes 'record' $1.2bn Europe-focused biopharma fund Jeito Capital has closed its second fund, raking in €1bn, which it claims is the largest ever raise for an independent European biopharma fund.

France-based #investment group #JeitoCapital has closed its second #fund, raking in €1 billion ($1.2 billion), which it claims is the largest ever raise for an independent #European fund dedicated to #biopharma.

pharmaphorum.com/news/jeito-c...

Insmed Drops Skin Therapy After Phase 2 Failure Insmed halted a Phase 2 skin-disorder candidate on Apr 8, 2026 after the trial missed its primary endpoint; the mid-stage failure raises near-term financing and pipeline concentration risks.

Insmed Drops Skin Therapy After Phase 2 Failure: Insmed halted a Phase 2 skin-disorder candidate on Apr 8, 2026 after the trial missed its primary endpoint; the mid-stage failure raises near-term financing and pipeline… 👈 Read full analysis #Insmed #SkinTherapy #ClinicalTrials #Healthcare #Biopharma

Allucent Strengthens Leadership to Enhance Drug Development Across Therapeutic Fields Allucent is enhancing its leadership team to focus on key therapeutic areas, aiming to integrate strategy with execution for improved drug development.

Allucent Strengthens Leadership to Enhance Drug Development Across Therapeutic Fields #USA #Drug_Development #CARY #Biopharma #Allucent

Scientific innovation starts with purpose.

Our team is united by one goal: advancing research that deepens understanding of neurological science and supports patients worldwide.

Learn more about who we are:
www.sklifescienceinc.com/innovation/

#Neuroscience #Innovation #Biopharma

Vaccines & Infectious Diseases Intelligence - LucidQuest Strategic intelligence for the vaccines landscape. Primary research, competitive strategy, congress coverage, and investment insights across infectious diseases.

💉 Vaccines & Infectious Diseases 🦠
#LucidQuest equips BioPharma & investors with real-time insights to outpace the curve.
📩 info@lqventures.com or http://dlvr.it/TRv7Ln
#Vaccines #InfectiousDiseases #BioPharma #DueDiligence #LifeScienceStrategy

Strategic & Tactical Competitive Insights Across Therapy Areas - LucidQuest Evidence-based strategic insights for biopharma. Primary intelligences, congress coverage, AI-powered wargames, and competitive monitoring from development through commercialization.

🧠 Competitive Insights for #BioPharma and #HealthTech 🚀
#LucidQuest arms #pharma & #biotech with real-time intel to outpace rivals from R&D to market.
📩 info@lqventures.com or http://dlvr.it/TRtDl5
#CompetitiveIntelligence #Strategy #MarketAccess

Matinas BioPharma Receives NYSE Notice Apr 3, 2026 NYSE issued a notice to Matinas BioPharma on Apr 3, 2026; company must typically respond in 45 days and may have up to 180 days to regain compliance.

Matinas BioPharma Receives NYSE Notice Apr 3, 2026: NYSE issued a notice to Matinas BioPharma on Apr 3, 2026; company must typically respond in 45 days and may have up to 180 days to regain compliance. 👈 Read full analysis #MatinasBioPharma #NYSE #StockMarket #Biopharma #Compliance

OneCyte and Kemp Proteins Form a Dynamic Alliance to Enhance Cell Line Development for Next-Gen Biologics OneCyte and Kemp Proteins have entered a strategic partnership aimed at revolutionizing cell line development for the biopharmaceutical landscape, addressing major industry challenges.

OneCyte and Kemp Proteins Form a Dynamic Alliance to Enhance Cell Line Development for Next-Gen Biologics #United_States #Frederick #Biopharma #OneCyte #Kemp_Proteins

Cingulate CEO Shane Schaffer brought in the experts to identify the unmet needs in ADHD leading to the development of CTx-1301. The process also led to $CING's Precision Timed Release (PTR) platform.
youtu.be/erPHd3VPI3Q
#Biotech #BioPharma #FDA

Jazz Pharmaceuticals Set to Make a Mark at 25th Annual Needham Healthcare Conference Jazz Pharmaceuticals will participate in the Needham Healthcare Conference, featuring key discussions on their innovative biopharmaceutical developments.

Jazz Pharmaceuticals Set to Make a Mark at 25th Annual Needham Healthcare Conference #Ireland #Dublin #Biopharma #Jazz_Pharmaceuticals #Needham_Conference

Transfection is a method used to insert foreign nucleic acids into eukaryotic cells. It modifies the genetic content of host cells, enabling the study of cellular processes, disease mechanisms, and gene therapy applications.

Welcome to Wednesday Words, where I will define one word used in biotechnology or biopharma each Wednesday morning!

If you want to learn more, check out sbee.link/qvxnbmjwaf
#wednesdaywords #biotechnology #biopharma #science

AEON Biopharma Reports Biosimilar Progress, Secures $3.5M AEON Biopharma on Mar 30, 2026 announced completion of analytical comparability work and a $3.5M financing, targeting an IND filing in Q4 2026 (Investing.com, Mar 30, 2026).

AEON Biopharma Reports Biosimilar Progress, Secures $3.5M: AEON Biopharma on Mar 30, 2026 announced completion of analytical comparability work and a $3.5M financing, targeting an IND filing in Q4… 👈 Read full analysis #Biopharma #Biosimilars #HealthcareInvestment #INDFilings #PharmaceuticalIndustry

Single Use Pump Market Size, Growth, Trends Report 2035 Single Use Pump Market projected to reach USD 12.93 Billion, at a CAGR of 13.52% during 2026 to 2035, driven by Advancements in biopharmaceutical manufacturing drive demand for innovative solutions in...

Sterility and flexibility for biopharma. Single-use pumps eliminate cleaning validation and cross-contamination risks, critical for flexible bioprocessing operations.
#SingleUsePump #Biopharma #Bioprocessing #PharmaceuticalManufacturing www.marketresearchfuture.com/reports/sing...

👀 What Exciting things are your molecules really doing? Introducing the EI-FLEX Pro and Pro HT - designed to reveal dynamics, binding, and aggregation in real time with the ultimate single-molecule resolution and no specialist setup > youtu.be/peLNtmqAVIM

#singlemolecule #lifescience #biopharma

Vaccines & Infectious Diseases Intelligence - LucidQuest Strategic intelligence for the vaccines landscape. Primary research, competitive strategy, congress coverage, and investment insights across infectious diseases.

💉 Vaccines & Infectious Diseases 🦠
#LucidQuest equips BioPharma & investors with real-time insights to outpace the curve.
📩 info@lqventures.com or http://dlvr.it/TRlK73
#Vaccines #InfectiousDiseases #BioPharma #DueDiligence #LifeScienceStrategy

Strategic & Tactical Competitive Insights Across Therapy Areas - LucidQuest Evidence-based strategic insights for biopharma. Primary intelligences, congress coverage, AI-powered wargames, and competitive monitoring from development through commercialization.

🧠 Competitive Insights for #BioPharma and #HealthTech 🚀
#LucidQuest arms #pharma & #biotech with real-time intel to outpace rivals from R&D to market.
📩 info@lqventures.com or http://dlvr.it/TRkKlL
#CompetitiveIntelligence #Strategy #MarketAccess

Single Use Pump Market Size, Growth, Trends Report 2035 Single Use Pump Market projected to reach USD 12.93 Billion, at a CAGR of 13.52% during 2026 to 2035, driven by Advancements in biopharmaceutical manufacturing drive demand for innovative solutions in...

Single-use pumps are transforming biopharmaceutical manufacturing by eliminating cross-contamination risks and reducing cleaning validation requirements.
#SingleUse #Biopharma #Bioprocessing #PharmaceuticalManufacturing www.marketresearchfuture.com/reports/sing...

biopharmaceutical project management by royed training

🚀 Advanced Certification in Biopharma Project Management
Not just PM — it’s execution mastery 🧬

From R&D → Regulatory → Market Access
Learn real-world, science-driven decision making

🔗 zurl.co/D1nyz

#Biopharma #ProjectManagement #RoyedTraining

A close-up of a newspaper headline that reads "Stem Cells" is shown next to an arrangement of colorful pills and a syringe, visually representing the concept of cell therapy using living cells from either a patient or a donor to fight disease or repair damage.

Welcome to Wednesday Words, where I will define one word used in biotechnology or biopharma each Wednesday morning!

If you want to learn more, check out: sbee.link/t6qp7wb93d
#wednesdaywords #biotechnology #biopharma #CellTherapy #RegenerativeMedicine #StemCellTherapy #science

Grifols Weighs IPO of US Biopharma Unit Grifols is considering an IPO for its US biopharma unit (Seeking Alpha, Mar 24, 2026); analysts cite a potential $4–8bn valuation and US plasma supplies ~60–70% of global collections.

Grifols Weighs IPO of US Biopharma Unit: Grifols is considering an IPO for its US biopharma unit (Seeking Alpha, Mar 24, 2026); analysts cite a potential $4–8bn valuation and US plasma supplies ~60–70% of global collections. 👈 Read full analysis #Grifols #IPO #Biopharma #Investing #Healthcare

#Congress | Find us this week at 𝗕𝗜𝗢-𝗘𝘂𝗿𝗼𝗽𝗲 𝗦𝗽𝗿𝗶𝗻𝗴 𝟮𝟬𝟮𝟲 in Lisbon, Portugal! #BIOEuropeSpring

🙋 Representing Ysios Capital: Arturo Urrios and Malgorzata Rogalska, Ph.D.

🔗 lnkd.in/d7ZGGGHC

🤝 Let’s connect in Lisbon!

#BIOEuropeSpring #Biotech #VentureCapital #Biopharma #EuropeanBiotech

ESA de acción prolongada de Sansheng Pharma (Rosai EPO alfa / Xinbi’ao) aprobada para anemia por ERC en hemodiálisis 💊

¿Menos dosis y mejor control de Hb?

🎥 Mira el video

#CKD #AnemiaRenal #Hemodiálisis #ESA #PharmaNews #Biopharma

Sartorius Launches Platform to Improve Cell Therapy Manufacturing Efficiency -- MedCloudInsider New system is designed to streamline production workflows and support scalability in advanced therapies.

Sartorius has launched the Eveo Cell Therapy Platform, a closed system designed to streamline cell therapy manufacturing from cell selection through final formulation.

See how Sartorius is rethinking cell therapy production: https://ow.ly/H6ec50Yw6f3

#CellTherapy #Biopharma #Biotech

LC/MS is transforming HCP analysis in biopharma.
Hear Alphalyse, host cell protein CRO, share insights on applying LC/MS for deeper characterization, covering regulatory aspects, strategy, and performance. #lcms #proteomics #biologics #biopharma #drugdevelopment

Shanghai start-up launches to develop trispecific antibodies Excalipoint Therapeutics has raised $68.7 million

A new start-up is launching out of Shanghai with $68.7 million and a plan to tackle cancer and autoimmune diseases with T-cell-engaging antibodies.

#biotech #biopharma 🧪

Vaccines & Infectious Diseases Intelligence - LucidQuest Strategic intelligence for the vaccines landscape. Primary research, competitive strategy, congress coverage, and investment insights across infectious diseases.

💉 Vaccines & Infectious Diseases 🦠
#LucidQuest equips BioPharma & investors with real-time insights to outpace the curve.
📩 info@lqventures.com or http://dlvr.it/TRZcq6
#Vaccines #InfectiousDiseases #BioPharma #DueDiligence #LifeScienceStrategy